Published • loading... • Updated
Blood pressure medication recalled nationwide under FDA’s Class II risk level
Inventia Healthcare Limited recalled about 13,567 bottles after the tablets failed dissolution tests, and the FDA said exposure could cause reversible harm.
- On Sept 17, 2026, the FDA issued a nationwide Class II recall for Inventia Healthcare Limited's 25 mg Chlorthalidone tablets. This classification indicates potential for temporary or medically reversible health consequences.
- Inventia Health initiated the recall after the medication failed to meet dissolution specifications, specifically impacting batch RISA24002 identified in the official alert.
- Approximately 13,567 bottles containing 100 pills each are affected by this recall, representing the total volume currently subject to the FDA safety alert.
- The same manufacturer previously recalled approximately 11,460 bottles in June, and FOX has reached out to Inventia Health for comment on the current recall.
- Information for this recall was sourced from an FDA alert issued on Sept 17, 2026, and previous reporting by LiveNOW from FOX, with the story reported from San Jose.
Insights by Ground AI
57 Articles
57 Articles
Koco News5+25 Reposted by 25 other sources
FDA elevates new blood pressure medication recall to Class II
On September 17, the FDA classified an ongoing voluntary recall of chlorthalidone tablets, which are used to treat high blood pressure, as a Class II recall.
·Oklahoma City, United States
Read Full Article
Coverage Details
Total News Sources57
Leaning Left3Leaning Right0Center51Last UpdatedBias Distribution94% Center
Bias Distribution
- 94% of the sources are Center
94% Center
C 94%
Factuality
To view factuality data please Upgrade to Premium
